<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.102021</article-id><article-id pub-id-type="publisher-id">TCM-40326</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210200000_73111260.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  咳喘六味合剂联合西医常规疗法治疗肥胖型哮喘(外寒内饮证)急性发作期临床疗效观察
  Clinical Effect Observation of Kechuan Liuwei Mixture Combined with Western Medicine Routine Therapy on Obesity Asthma of Cold Type in Acute Attack Period
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>唐</surname><given-names>凌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>方</surname><given-names>泓</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>银根</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>喻</surname><given-names>晓</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>上海中医药大学附属龙华医院，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>02</month><year>2021</year></pub-date><volume>10</volume><issue>02</issue><fpage>150</fpage><lpage>156</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：观察咳喘六味合剂联合西医常规疗法治疗肥胖型哮喘(外寒内饮证)急性发作期患者的临床疗效。方法：将78例肥胖型哮喘(外寒内饮证)急性发作期患者随机分为对照组与治疗组，对照组患者给予平喘对症等西药基础治疗；治疗组患者在给予基础治疗的同时加用咳喘六味合剂治疗，疗程均为2周。观察两组患者治疗前后的中医证候积分、哮喘控制水平测试量表(ACT)，生存质量评分(AQLQ)、肺功能[用力肺活量(FVC)、第一秒用力呼气容积(FEV1)、最大呼气流速(PEF)]的变化。结果：经治后对照组中医症候总有效率为75%，治疗组为88.1%，两组比较有统计学差异(P &lt; 0.05)；两组中医证候积分(包括喘息、气短、咳嗽、咯痰、哮鸣音)治疗后均较前改善(P &lt; 0.05)，且在改善喘息、气短、咳嗽、咯痰方面，治疗组优于对照组(P &lt; 0.05)；两组治疗后AQLQ评分均较前改善，且治疗组改善程度优于对照组(P &lt; 0.05)；两组治疗后ACT评分均较前好转，治疗组改善明显优于对照组(P &lt; 0.01)；两组治疗后肺功能FVC、FEV1、PEF均较前改善(P &lt; 0.05)，且治疗组改善FEV1、PEF更优于对照组(P &lt; 0.05)。结论：咳喘六味合剂联合西医常规疗法治疗肥胖型哮喘(外寒内饮证)急性发作期患者临床疗效明显，可明显减轻临床症状，更好地控制哮喘发作，提高生存质量，改善肺功能，值得临床进一步推广。 Objective: To observe the clinical effect of Kechuan Liuwei Mixture combined with western medicine routine therapy on obese asthma of cold type in acute attack period. Methods: 78 patients with cold type of obese asthma were randomly divided into control group and treatment group. Patients in the control group were given western medicine routine therapy. Patients in the treatment group were given basic treatment at the same time with Kechuan Liuwei Mixture treatment, the course of treatment was 2 weeks. The changes of TCM syndrome score, asthma control level test scale (ACT), quality of life score (AQLQ), lung function [forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow rate (PEF)] before and after treatment in 2 groups were observed. Results: After treatment, the total effective rate of TCM syndrome was 75% in the control group and 88.1% in the treatment group, and there was a statistical difference between the two groups (P &lt; 0.05). The TCM syndrome scores (including wheezing, shortness of breath, cough, sputum and wheezing) in both groups were improved after treatment (P &lt; 0.05), and the treatment group was better than the control group in improving wheezing, shortness of breath, cough and sputum (P &lt; 0.05); AQLQ scores in both groups were improved, and the improvement degree in treatment group was better than that in control group (P &lt; 0.05). ACT scores in both groups were improved, and the improvement in treatment group was significantly better than that in control group (P &lt; 0.01). Lung function FVC, FEV1 and PEF were improved in both groups (P &lt; 0.05), and FEV1 and PEF were improved in the treatment group more than in the control group (P &lt; 0.05). Conclusion: The clinical efficacy of Kechuan Liuwei Mixture combined with western medicine routine therapy in the treatment of cold type obese asthma acute attack patients is obvious, which can significantly reduce the clinical symptoms, better control the asthma attacks, improve the quality of life, improve lung function and be worthy of further clinical promotion. 
   
   
    
  
 
</p></abstract><kwd-group><kwd>肥胖型哮喘，咳喘六味合剂，外寒内饮证，急性发作, Obesity Asthma</kwd><kwd> Kechuan Liuwei Mixture</kwd><kwd> Cold Type</kwd><kwd> Acute Attack Period</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：观察咳喘六味合剂联合西医常规疗法治疗肥胖型哮喘(外寒内饮证)急性发作期患者的临床疗效。方法：将78例肥胖型哮喘(外寒内饮证)急性发作期患者随机分为对照组与治疗组，对照组患者给予平喘对症等西药基础治疗；治疗组患者在给予基础治疗的同时加用咳喘六味合剂治疗，疗程均为2周。观察两组患者治疗前后的中医证候积分、哮喘控制水平测试量表(ACT)，生存质量评分(AQLQ)、肺功能[用力肺活量(FVC)、第一秒用力呼气容积(FEV1)、最大呼气流速(PEF)]的变化。结果：经治后对照组中医症候总有效率为75%，治疗组为88.1%，两组比较有统计学差异(P &lt; 0.05)；两组中医证候积分(包括喘息、气短、咳嗽、咯痰、哮鸣音)治疗后均较前改善(P &lt; 0.05)，且在改善喘息、气短、咳嗽、咯痰方面，治疗组优于对照组(P &lt; 0.05)；两组治疗后AQLQ评分均较前改善，且治疗组改善程度优于对照组(P &lt; 0.05)；两组治疗后ACT评分均较前好转，治疗组改善明显优于对照组(P &lt; 0.01)；两组治疗后肺功能FVC、FEV1、PEF均较前改善(P &lt; 0.05)，且治疗组改善FEV1、PEF更优于对照组(P &lt; 0.05)。结论：咳喘六味合剂联合西医常规疗法治疗肥胖型哮喘(外寒内饮证)急性发作期患者临床疗效明显，可明显减轻临床症状，更好地控制哮喘发作，提高生存质量，改善肺功能，值得临床进一步推广。</p></sec><sec id="s2"><title>关键词</title><p>肥胖型哮喘，咳喘六味合剂，外寒内饮证，急性发作</p></sec><sec id="s3"><title>Clinical Effect Observation of Kechuan Liuwei Mixture Combined with Western Medicine Routine Therapy on Obesity Asthma of Cold Type in Acute Attack Period<sup> </sup></title><p>Ling Tang, Hong Fang, Yingen Wu, Xiao Yu<sup>*</sup></p><p>Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai</p><p><img src="//html.hanspub.org/file/3-2270645x5_hanspub.png" /></p><p>Received: Jan. 3<sup>r</sup><sup>d</sup>, 2021; accepted: Jan. 30<sup>th</sup>, 2021; published: Feb. 8<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/3-2270645x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To observe the clinical effect of Kechuan Liuwei Mixture combined with western medicine routine therapy on obese asthma of cold type in acute attack period. Methods: 78 patients with cold type of obese asthma were randomly divided into control group and treatment group. Patients in the control group were given western medicine routine therapy. Patients in the treatment group were given basic treatment at the same time with Kechuan Liuwei Mixture treatment, the course of treatment was 2 weeks. The changes of TCM syndrome score, asthma control level test scale (ACT), quality of life score (AQLQ), lung function [forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow rate (PEF)] before and after treatment in 2 groups were observed. Results: After treatment, the total effective rate of TCM syndrome was 75% in the control group and 88.1% in the treatment group, and there was a statistical difference between the two groups (P &lt; 0.05). The TCM syndrome scores (including wheezing, shortness of breath, cough, sputum and wheezing) in both groups were improved after treatment (P &lt; 0.05), and the treatment group was better than the control group in improving wheezing, shortness of breath, cough and sputum (P &lt; 0.05); AQLQ scores in both groups were improved, and the improvement degree in treatment group was better than that in control group (P &lt; 0.05). ACT scores in both groups were improved, and the improvement in treatment group was significantly better than that in control group (P &lt; 0.01). Lung function FVC, FEV1 and PEF were improved in both groups (P &lt; 0.05), and FEV1 and PEF were improved in the treatment group more than in the control group (P &lt; 0.05). Conclusion: The clinical efficacy of Kechuan Liuwei Mixture combined with western medicine routine therapy in the treatment of cold type obese asthma acute attack patients is obvious, which can significantly reduce the clinical symptoms, better control the asthma attacks, improve the quality of life, improve lung function and be worthy of further clinical promotion.</p><p>Keywords:Obesity Asthma, Kechuan Liuwei Mixture, Cold Type, Acute Attack Period</p><disp-formula id="hanspub.40326-formula24"><graphic xlink:href="//html.hanspub.org/file/3-2270645x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-2270645x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-2270645x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>支气管哮喘(简称哮喘)是以气道炎症为主的多种病理因素参与的慢性呼吸道疾病 [<xref ref-type="bibr" rid="hanspub.40326-ref1">1</xref>]。临床主要表现为反复喘息、咳嗽、气急、胸闷等，听诊可及以呼气相为主的弥漫性哮鸣音。哮喘在儿童和成人中有许多表型，遗传、免疫、环境等多种因素可以诱发、加重哮喘，其异质性令治疗尤为困难。肥胖症已被世界卫生组织确认为流行病，2014年GINA (The Global Initiative for Asthma)把肥胖定为哮喘发生和加重的重要宿主因素之一，提出肥胖型哮喘是哮喘新的分型，但其机制尚未完全明确，这一特殊类型的哮喘患者临床表现更重、治疗更不敏感、病情控制更不稳定 [<xref ref-type="bibr" rid="hanspub.40326-ref2">2</xref>]。深入寻找防治肥胖型哮喘的新的治疗方法和药物，对肥胖型哮喘的防治具有重要的意义。</p><p>咳喘六味合剂为上海中医药大学附属龙华医院吴银根教授根据多年中医药防治哮喘经验而创制，前期通过临床观察发现，咳喘六味合剂能有效提高临床有效率，改善患者肺功能，下调血浆IgE、ECP、IL-4、IL-5含量，说明该方能降低哮喘患者气道阻力，改善哮喘患者的过敏体质，并具有抑制气道炎症的作用 [<xref ref-type="bibr" rid="hanspub.40326-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.40326-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.40326-ref5">5</xref>]，但对肥胖型哮喘这一特殊类型的难治性哮喘未作深入观察，本研究拟通过使用咳喘六味合剂联合西医常规疗法治疗肥胖型哮喘(外寒内饮证)急性发作期患者，结果证实临床疗效显著，现总结如下。</p></sec><sec id="s6"><title>2. 临床资料</title><sec id="s6_1"><title>2.1. 病例来源</title><p>选择2018年3月~2019年3月上海中医药大学附属龙华医院呼吸科门诊就诊的肥胖型哮喘患者78例；其中治疗组42例，女性26例，男性16例，最大年龄72周岁，最小年龄28周岁，平均年龄47.65 &#177; 6.25岁，哮喘病情属中度者12例，轻度者30例；对照组36例，女性23例，男性13，最大年龄73周岁，最小年龄26周岁，平均年龄53.64 &#177; 7.28岁，哮喘患者病情中度者14例，病情轻度者22例。两组患者年龄、性别、不同发作程度人数分布等基线资料无显著性差异(P &gt; 0.05)，具有可比性。</p></sec><sec id="s6_2"><title>2.2. 纳入排除标准</title><p>1)纳入标准：① BMI大于25；② 符合中华医学会呼吸病学分会哮喘学组2020年修订的《支气管哮喘防治指南(2020年版)》 [<xref ref-type="bibr" rid="hanspub.40326-ref6">6</xref>] 中支气管哮喘的诊断标准及病情分级标准，确诊为处于急性发作期轻度或中度患者；③ 签署知情同意，并接受本药物治疗的患者；④ 符合中华中医药学会肺系病专业委员会/中国民族医药学会肺病分会2016年制定《支气管哮喘中医证候诊断标准(2016版)》符合外寒内饮证的临床标准 [<xref ref-type="bibr" rid="hanspub.40326-ref7">7</xref>]；⑤ 年龄在18~75周岁之间。</p><p>2) 排除标准：① 哮喘患者处于临床缓解期和慢性持续期的患者；② 重度哮喘及致命性哮喘；③患者年龄小于18周岁或大于75周岁的患者；④ 孕妇或哺乳期的妇女；⑤ 合并有严重心、肝、肾疾病且功能严重障碍的患者；⑥ 不符合纳入标准，有精神或认知障碍，依从性差者。</p><p>3) 中止标准：① 在研究过程中发生严重不良事件，出现并发症不能继续完成试验者；② 因个人原因无法完成观察期内临床观察者；③ 需要采取积极措施治疗的病情加重者。</p></sec><sec id="s6_3"><title>2.3. 治疗方法</title><p>1) 对照组：西医常规治疗，包括吸氧、化痰、平喘、解痉、抗感染等治疗，根据病情必要时使用舒利迭(葛兰素史克，50/250 μg)吸入，1吸/次，2次/天。</p><p>2) 治疗组：在西医常规治疗的基础上同时加用咳喘六味合剂(上海中医药大学附属龙华医院院内制剂，沪药制字Z04170941)，15 ml，一天三次，饭后口服。</p><p>3) 以上两组均治疗观察2周。</p></sec><sec id="s6_4"><title>2.4. 观察指标</title><p>1) 中医证候积分：参照2002年临床试验研究国家药品监督管理局《中药新药临床研究指导原则》 [<xref ref-type="bibr" rid="hanspub.40326-ref8">8</xref>]，观察两组患者治疗前后哮喘主要症状及体征(包括喘息、气短、咳嗽、咯痰、哮鸣音)的变化情况，均采用4级标准计分：0分为无症状；1分为轻度；2分为中度；3分为重度。</p><p>2) ACT评分：采用哮喘控制水平测试量表(由5个问题评分组成，哮喘控制温5分，部分控制为20~24分，未控制为19分)，记录治疗前后ACT评分。</p><p>3) 生存质量评分 [<xref ref-type="bibr" rid="hanspub.40326-ref9">9</xref>] (Asthma quality of life questionnaire, AQLQ)：共有35条项目，包括活动受限(1~12)，哮喘症状(13~20)，心理状况(22~26)，对刺激源的反应(27~31)，对自身健康的关心(32~35)，按5分制评分，1分最差，5分最好。</p><p>4) 肺功能检测：检测患者治疗前后肺功能，主要记录FVC、FEV1、PEF数值。</p></sec><sec id="s6_5"><title>2.5. 疗效判定标准</title><p>疗效评定标准参照《中药新药临床研究指导原则》中哮喘疗效标准 [<xref ref-type="bibr" rid="hanspub.40326-ref8">8</xref>] 制定：依据临床症状、用药情况、FEV1 (或PEF)实测值以及FEV1(或PEF)占预计值百分比，分为临床控制、显效、好转、无效4个疗效等级。</p></sec><sec id="s6_6"><title>2.6. 统计分析</title><p>数据统计分析描述用SPSS18.0统计软件完成，描述性分析中对计量资料采用均值 &#177; 标准差( χ &#175; &#177; s )表示。对于符合正态分布、方差齐性的计量资料采用方差分析，如不符合，则采用Wilcoxon秩和检验；计数资料采用卡方检验；等级资料使用Wilcoxon秩和检验。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 中医症候疗效分析</title><p>经治后，治疗组和对照组的中医症候疗效有效率分别为88.1%和75%，治疗组优于对照组(P &lt; 0.05)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Analysis of curative effect of TCM syndrome</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >临床控制</th><th align="center" valign="middle" >显效</th><th align="center" valign="middle" >好转</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >总有效率</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >75%</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >88.1%<sup>△</sup></td></tr></tbody></table></table-wrap><p>表1. 中医证候疗效分析</p><p>注：<sup>△</sup>表示对照组与治疗组治疗后组间比较有差异(P &lt; 0.05)。</p></sec><sec id="s7_2"><title>3.2. 两组中医症候总积分比较</title><p>经治后，两组中医证候积分均较治疗前改善(P &lt; 0.05)，且在改善喘息、气短、咳嗽、咯痰方面优于对照组(P &lt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of TCM syndrome scores between two groups ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >喘息</th><th align="center" valign="middle" >气短</th><th align="center" valign="middle" >咳嗽</th><th align="center" valign="middle" >咯痰</th><th align="center" valign="middle" >哮鸣音</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >对照组</td><td align="center" valign="middle"  rowspan="2"  >36</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >2.9 &#177; 0.74</td><td align="center" valign="middle" >2.75 &#177; 0.66</td><td align="center" valign="middle" >2.35 &#177; 0.46</td><td align="center" valign="middle" >2.52 &#177; 0.59</td><td align="center" valign="middle" >2.95 &#177; 0.89</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >1.67 &#177; 0.68<sup>*</sup></td><td align="center" valign="middle" >1.68 &#177; 0.7<sup>*</sup></td><td align="center" valign="middle" >1.37 &#177; 0.17<sup>*</sup></td><td align="center" valign="middle" >1.32 &#177; 0.17<sup>*</sup></td><td align="center" valign="middle" >1.43 &#177; 0.2<sup>*</sup></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >治疗组</td><td align="center" valign="middle"  rowspan="2"  >42</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >2.91 &#177; 0.75</td><td align="center" valign="middle" >2.99 &#177; 0.87</td><td align="center" valign="middle" >2.43 &#177; 0.42</td><td align="center" valign="middle" >2.48 &#177; 0.46</td><td align="center" valign="middle" >2.91 &#177; 0.83</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >1.15 &#177; 0.16<sup>*△</sup></td><td align="center" valign="middle" >1.1 &#177; 0.12<sup>*△</sup></td><td align="center" valign="middle" >1.05 &#177; 0.11<sup>*△</sup></td><td align="center" valign="middle" >1.15 &#177; 0.31<sup>*△</sup></td><td align="center" valign="middle" >1.38 &#177; 0.16<sup>*</sup></td></tr></tbody></table></table-wrap><p>表2. 两组中医证候积分比较( x &#175; &#177; s )</p><p>注：<sup>*</sup>表示各组内治疗前后比较有差异(P &lt; 0.05)，<sup>△</sup>表示对照组与治疗组治疗后组间比较有差异(P &lt; 0.05)。</p></sec><sec id="s7_3"><title>3.3. 生存质量评分(AQLQ)比较</title><p>两组治疗后AQLQ评分均较前改善(P &lt; 0.05)，治疗组优于对照组(P &lt; 0.05)。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparative analysis of quality of life score (AQLQ) ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >138.21 &#177; 14.58</td><td align="center" valign="middle" >145.99 &#177; 15.20<sup>*</sup></td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >136.54 &#177; 13.37</td><td align="center" valign="middle" >153.06 &#177; 16.44<sup>*△</sup></td></tr></tbody></table></table-wrap><p>表3. 生存质量评分(AQLQ)比较分析( x &#175; &#177; s )</p><p>注：<sup>*</sup>表示各组内治疗前后比较有差异(P &lt; 0.05)，<sup>△</sup>表示对照组与治疗组治疗后组间比较有差异(P &lt; 0.05)。</p></sec><sec id="s7_4"><title>3.4. 哮喘控制测试评分(ACT)比较</title><p>两组治疗后ACT评分较前改善(P &lt; 0.05)，治疗组改善明显优于对照组(P &lt; 0.01)。见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of ACT ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >18.21 &#177; 2.61</td><td align="center" valign="middle" >19.25 &#177; 1.73<sup>*</sup></td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >17.61 &#177; 2.42</td><td align="center" valign="middle" >22.68 &#177; 2.28<sup>*△△</sup></td></tr></tbody></table></table-wrap><p>表4. 哮喘控制测试评分比较( x &#175; &#177; s )</p><p>注：<sup>*</sup>表示各组内治疗前后比较有差异(P &lt; 0.05)，<sup>△</sup>表示对照组与治疗组治疗后组间比较有差异(P &lt; 0.05)。</p></sec><sec id="s7_5"><title>3.5. 治疗前后肺功能的比较</title><p>两组治疗后肺功能FVC、FEV1、PEF较前均改善(P &lt; 0.05，P &lt; 0.01)，在改善FEV1、PEF方面，治疗组优于对照组(P &lt; 0.05)。见表5。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Comparison of lung function ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >n</th><th align="center" valign="middle"  colspan="2"  >FVC (L)</th><th align="center" valign="middle"  colspan="2"  >FEV1 (L)</th><th align="center" valign="middle"  colspan="2"  >PEF (L/S)</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >2.36 &#177; 0.48</td><td align="center" valign="middle" >2.98 &#177; 0.69<sup>*</sup></td><td align="center" valign="middle" >1.56 &#177; 0.2</td><td align="center" valign="middle" >1.92 &#177; 0.31<sup>*</sup></td><td align="center" valign="middle" >2.67 &#177; 0.62</td><td align="center" valign="middle" >4.16 &#177; 0.84<sup>**</sup></td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >2.3 &#177; 0.43</td><td align="center" valign="middle" >3.07 &#177; 0.74<sup>*</sup></td><td align="center" valign="middle" >1.49 &#177; 0.16</td><td align="center" valign="middle" >2.39 &#177; 0.47**<sup>△</sup></td><td align="center" valign="middle" >2.61 &#177; 0.59</td><td align="center" valign="middle" >4.88 &#177; 0.96<sup>**</sup><sup>△</sup></td></tr></tbody></table></table-wrap><p>表5. 肺功能比较( x &#175; &#177; s )</p><p>注：<sup>*</sup>示各组内治疗前后比较有差异(P &lt; 0.05)，<sup>**</sup>表示各组内治疗前后比较有显著差异(P &lt; 0.01)，<sup>△</sup>表示对照组与治疗组治疗后组间比较有差异(P &lt; 0.05)。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>支气管哮喘是具异质性的呼吸系统疾病，由多种细胞因子参与的慢性气道炎症，以喘鸣，气短，胸闷和咳嗽为主要症状，常伴有限制性通气功能障碍 [<xref ref-type="bibr" rid="hanspub.40326-ref6">6</xref>]。肥胖型哮喘是哮喘的一种新的表型，以往临床研究发现，哮喘的发病率与肥胖发病率的增高呈正相关，而且肥胖型哮喘患者的病情较普通哮喘患者症状更严重，更容易反复发作，常规治疗反应较差，是临床治疗棘手的难题 [<xref ref-type="bibr" rid="hanspub.40326-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40326-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40326-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.40326-ref13">13</xref>]。虽然对糖皮质激素治疗不敏感，目前仍是其主要的治疗手段，但是肥胖容易伴随血脂、血糖等代谢紊乱问题，而激素的应用更加重这些代谢问题，引发一系列副反应。因此，寻找防治肥胖型哮喘这一特殊类型的难治性哮喘的有效药物已经成为广大学者关注的热点。</p><p>中医对哮喘的认识古已有之，可归属于“哮证”、“哮病”等，是一种反复发作的痰鸣气喘疾患，哮病的发生与“痰”密切相关，乃宿痰内伏于肺，遇诱因引触，以致痰阻气道，气道挛急，肺失肃降，肺气上逆而发哮喘。肥胖与痰、湿、气虚等关系密切，清代叶天士指出：“夫肌肤柔白属气虚，外似丰溢，里真大怯，盖阳虚之体，惟多痰多湿……”，阐明肥胖人本虚标实的病理属性：气虚阳虚为本、多痰多湿为标。先天禀赋不足，伏痰于肺是哮病发生的根本病机。因此，我们认为，痰湿是引起肥胖和哮喘的共同病理因素，也是联系肥胖和哮喘的核心。痰饮为脏腑功能低下，阳气不足导致的病理产物，气行不畅、痰饮内停进一步可导致痰瘀交阻。仲景倡“以温药和之”，温散痰饮兼以温阳化气，恢复脏腑正常生理功能，消除发病夙根。吴鞠通提出的“盖饮为阴邪，非温不化”恰合仲景之意。吴银根教授创制的咳喘六味合剂方以附子、麻黄为君，辛温大热，附子温少阴之真阳，麻黄发太阳之表寒，从而达到温肾散寒、宣肺平喘之功。细辛辛温香窜既助麻黄以解表散外寒，又能助附子以温阳以祛里寒。桃仁化痰祛瘀，以解哮喘痰瘀之宿根，共同为臣；佐以苦寒之黄芩、虎耳草，一可清肺化痰，一可兼制附子、麻黄等温热药物之辛燥太过，还能兼顾其病机转化，预防哮证因反复发作，本质之寒久羁，郁而化热。全方标本兼顾，寒温并用，宣肃同施，既针对哮病阳虚痰饮伏肺之宿根，又针对肥人多寒湿的病理特征，丰富了“病痰饮者，当以温药和之”的内涵。</p><p>咳喘六味合剂联合常规疗法治疗支气管哮喘急性发作期(外寒内饮证)患者，可显著改善患者中医证候积分，尤其在减轻喘促、气短、咳嗽、咯痰方面优于单纯西医治疗组；生存质量积分较单纯西医治疗组提高更明显，患者生活自理能力、心理状态、对刺激源的反应以及对自身健康的重视都得到提升，更有利于疾病的预后；哮喘控制ACT评分改善程度明显优于单纯西医治疗组；联合治疗也可以一定程度改善肺功能，尤其在FEV1、PEF方面优于单纯西医治疗组。</p><p>咳喘六味合剂治疗外寒内饮证哮喘急性发作期(轻、中度)的整体疗效优于单纯西医治疗组，今后可进一步增大样本量、延长观察周期进行临床研究。</p></sec><sec id="s9"><title>基金项目</title><p>国家自然基金青年基金(81703988)龙华医院科技创新项目(CX202006)。</p></sec><sec id="s10"><title>文章引用</title><p>唐 凌,方 泓,吴银根,喻 晓. 咳喘六味合剂联合西医常规疗法治疗肥胖型哮喘(外寒内饮证)急性发作期临床疗效观察Clinical Effect Observation of Kechuan Liuwei Mixture Combined with Western Medicine Routine Therapy on Obesity Asthma of Cold Type in Acute Attack Period[J]. 中医学, 2021, 10(02): 150-156. https://doi.org/10.12677/TCM.2021.102021</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40326-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Global Initiative for Asthma (2020) Global Strategy for Asthma Management and Prevention.  
http://www.ginaasthma.org/</mixed-citation></ref><ref id="hanspub.40326-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Boulet, L.P., FitzGerald, J.M. and Reddel, H.K. (2015) The Revised 2014 GINA Strategy Report: Opportunities for Change. Current Opinion in Pulmonary Medicine, 21, 1-7. &lt;br&gt;https://doi.org/10.1097/MCP.0000000000000125</mixed-citation></ref><ref id="hanspub.40326-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">穆颖, 倪伟, 邹煜明. 咳喘六味合剂结合常规疗法治疗哮喘慢性持续期临床观察[J]. 上海中医药杂志, 2014, 48(6): 51-52.</mixed-citation></ref><ref id="hanspub.40326-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">倪伟, 张惠勇. 咳喘落治疗支气管哮喘寒哮证多中心临床研究[J]. 上海中医药大学学报, 2007, 21(3): 43-45.</mixed-citation></ref><ref id="hanspub.40326-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">吴银根, 于素霞, 张惠勇, 等. 咳喘落治疗175例哮喘临床总结[J]. 上海中医药杂志, 2000, 34(9): 19-21.</mixed-citation></ref><ref id="hanspub.40326-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2020年版)[J]. 中华结核和呼吸杂志, 2020, 43(12): 1023-1048.</mixed-citation></ref><ref id="hanspub.40326-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">中华中医药学会肺系病专业委员会/中国民族医药学会肺病分会. 支气管哮喘中医证候诊断标准(2016版)[J]. 中医杂志, 2016, 57(22): 1978-1980.</mixed-citation></ref><ref id="hanspub.40326-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">郑筱萸. 中药新药临床研究指导原则(试行)[S]. 北京: 中国医药科技出版社, 2002: 60-66.</mixed-citation></ref><ref id="hanspub.40326-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">李凡, 蔡映云. 支气管哮喘生存质量评估表的制定、评估和临床应用[J]. 现代康复, 2001, 5(2): 18-19.</mixed-citation></ref><ref id="hanspub.40326-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Gibeon, D., Batuwita, K., Osmond, M., et al. (2013) Obesity-Associated Severe Asthma Represents a Distinct Clinical Phenotype: Analysis of the British Thoracic Society Difficult Asthma Registry Patient Cohort According to BMI. Chest, 143, 406-414. &lt;br&gt;https://doi.org/10.1378/chest.12-0872</mixed-citation></ref><ref id="hanspub.40326-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Dixon, A.E. and Poynter, M.E. (2016) Mechanisms of Asthma in Obesity: Pleiotropic Aspects of Obesity Produce Distinct Asthma Phenotypes. American Journal of Respiratory Cell and Molecular Biology, 54, 601-608.  
&lt;br&gt;https://doi.org/10.1165/rcmb.2016-0017PS</mixed-citation></ref><ref id="hanspub.40326-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ather, J.L., Poynter, M.E. and Dixon, A.E. (2015) Immunological Characteristics and Management Considerations in Obese Patients with Asthma. Expert Review of Clinical Immunology, 11, 793-803.  
&lt;br&gt;https://doi.org/10.1586/1744666X.2015.1040394</mixed-citation></ref><ref id="hanspub.40326-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Manion, A.B. and Velsor-Friedrich, B. (2016) Quality of Life and Health Outcomes in Overweight and Non-Overweight Children with Asthma. Journal of Pediatric Health Care, 31, 37-45.  
&lt;br&gt;https://doi.org/10.1016/j.pedhc.2016.01.005</mixed-citation></ref></ref-list></back></article>